AbbVie Buys Apogee
AbbVie is acquiring Apogee Therapeutics, a biotech company developing an experimental eczema drug, for $10.9 billion
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
6 results loaded, newest first. End of these results.
AbbVie Buys Apogee
AbbVie is acquiring Apogee Therapeutics, a biotech company developing an experimental eczema drug, for $10.9 billion
AbbVie Buys Apogee
AbbVie is acquiring Apogee Therapeutics, a biotech company developing an experimental eczema drug, for $10.9 billion.
AbbVie Buys Apogee
AbbVie is closing in on a nearly $11 billion deal for biotech company Apogee Therapeutics
AbbVie Buys Apogee
AbbVie is closing in on a nearly $11 billion deal to acquire biotech company Apogee Therapeutics
AbbVie Buys Biotech
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.